Oric Pharmaceuticals (ORIC) vs Replimune Group (REPL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Replimune Group (REPL) has outperformed Oric Pharmaceuticals (ORIC) over the past year, gaining 183.9% versus a loss of 14.9%. Over five years, ORIC leads with a -26.0% price change compared with -56.2% for REPL. Oric Pharmaceuticals is the larger company by market cap ($1.24 billion vs $1.24 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ORIC | REPL |
|---|---|---|
| Share price | $12.01 | $13.20 |
| Market cap | $1.24B | $1.24B |
| 1-day change | +0.25% | -0.38% |
| YTD return | +46.82% | +35.80% |
| 1-year return | -14.94% | +183.87% |
| 5-year return | -26.00% | -56.22% |
| EPS (TTM) | $-1.33 | $-3.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.68 | $16.33 |
| 52-week low | $7.23 | $1.50 |
| Distance from 52-week high | -18.19% | -19.17% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +78.43% | +47.73% |
| Average volume | 1.47M | 4.20M |
| Shares outstanding | 103.65M | 94.22M |
| Employees | 111 | 465 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- REPL has outperformed ORIC by 198.8 percentage points over the past year.
About Oric Pharmaceuticals
ORIC stock →ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study.
Healthcare · Biotechnology · 111 employees
About Replimune Group
REPL stock →Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer.
Healthcare · Biotechnology · 465 employees
ORIC vs REPL FAQ
Which is bigger, Oric Pharmaceuticals or Replimune Group?
Oric Pharmaceuticals (ORIC) is larger, with a market capitalization of $1.24B compared with $1.24B for Replimune Group (REPL).
Which stock has performed better over the past year, ORIC or REPL?
REPL returned +183.87% over the past 12 months, compared with -14.94% for ORIC (price return, excluding dividends). Past performance does not predict future results.
Are Oric Pharmaceuticals and Replimune Group in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.